Last reviewed · How we verify
NCT04631718
MRI QSM Imaging for Iron Overload
trial testing Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) in Hemochromatosis in 63 participants. Completed in 29 April 2024.
29 April 2024
Quick facts
| Lead sponsor | University of Wisconsin, Madison |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 18 January 2022 |
| Primary completion | 29 April 2024 |
| Estimated completion | 29 April 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
Conditions studied
- Hemochromatosis — all drugs for Hemochromatosis →
- Iron Overload — all drugs for Iron Overload →
Sponsor
University of Wisconsin, Madison
Who can join
5 and older, any sex, with Hemochromatosis or Iron Overload. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron deposition. In this work, study team will develop and optimize advanced data acquisition and image reconstruction methods to enable QSM of the abdomen. Further, investigators will determine the accuracy, repeatability, and reproducibility of abdominal QSM for iron quantification in patients with liver iron overload. Excessive accumulation of iron in various organs, including the liver, which affects both adult and pediatric populations, is toxic and requires treatment aimed at reducing body iron stores. Accurate assessment of liver iron concentration is critical for the detection and staging of iron overload as well as for longitudinal monitoring during treatment. In summary, this project will develop a novel MRI-based QSM technique designed for the abdomen and will validate it in pediatric and adult patients with liver iron overload. Upon successful validation, QSM will provide accurate, repeatable, and reproducible quantification of LIC based on a fundamental property of tissue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04631718
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemochromatosis
Currently open trials in the same condition.
- NCT00007150 — Treatment of Hemochromatosis · Phase 2 · active not recruiting
Other University of Wisconsin, Madison trials
Trials by the same sponsor.
- NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
- NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
- NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
- NCT07470723 — The ORIGIN-FH Study · NA · recruiting
- NCT06975657 — Well-being Skills for Reentry · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04631718 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
- Last refreshed: 9 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04631718.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing